P. Norman
Feb 1, 2008
Citations
0
Influential Citations
0
Citations
Journal
Expert Opinion on Therapeutic Patents
Abstract
Two applications separately claim specific crystalline forms of 3,5-dibromo-N-[(2S)-2-(-4-fluorophenyl)-4-(3-morpholin-4-ylazetidin-1-yl)butyl]-N-methylbenzamide, a NK1/NK2 antagonist that was first claimed in WO2004110344. The use of the compound for treating a diverse range of disorders, including asthma, gastrointestinal diseases, pain and depression, is claimed.